KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vir Biotechnology (VIR) Gross Margin (2020 - 2025)

Vir Biotechnology's Gross Margin history spans 6 years, with the latest figure at 99.09% for Q2 2025.

  • For Q2 2025, Gross Margin rose 78.0% year-over-year to 99.09%; the TTM value through Jun 2025 reached 96.08%, down 264.0%, while the annual FY2025 figure was 99.96%, 110.0% up from the prior year.
  • Gross Margin for Q2 2025 was 99.09% at Vir Biotechnology, down from 100.0% in the prior quarter.
  • Across five years, Gross Margin topped out at 100.0% in Q1 2021 and bottomed at 31.28% in Q2 2022.
  • The 5-year median for Gross Margin is 97.44% (2024), against an average of 92.81%.
  • The largest annual shift saw Gross Margin tumbled -6804bps in 2022 before it surged 6814bps in 2023.
  • A 5-year view of Gross Margin shows it stood at 93.08% in 2021, then decreased by -6bps to 87.86% in 2022, then increased by 8bps to 95.25% in 2023, then decreased by -1bps to 94.47% in 2024, then increased by 5bps to 99.09% in 2025.
  • Per Business Quant, the three most recent readings for VIR's Gross Margin are 99.09% (Q2 2025), 100.0% (Q1 2025), and 94.47% (Q4 2024).